Login to Your Account

financings NEWS

Apellis Pharmaceuticals Inc.'s $47.1 million in series D money will let the company reach "some inflection points in rare diseases and geographic atrophy [GA] in the next year or so," general counsel David Watson told BioWorld Today.

Avexis Inc. made it out the door with an upsized IPO, pricing 4.75 million common shares at $20 apiece – the midpoint of its intended range – to raise $95 million. But the company's shares encountered headwinds as soon as they stepped off the stoop.

Despite pricing well below range, an upsized IPO by cystic fibrosis drug developer Proteostasis Therapeutics Inc.  fell 17 percent during its first day of trading Thursday.

More financings Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: